Oral Mucositis


  • Berislav Topić Department of Medical Sciences, Academy of Sciences and Arts of Bosnia and Herzegovina, Sarajevo
  • Ana Cekić-Arambašin Department of Oral Medicine, Zagreb University School of Dental Medicine, Zagreb


Mucositis, Stomatitis, Antineoplastic Agents, Radiation Injuries, Radiotherapy, Gelclair, Review


Oral mucositis develops in 100% of patients receiving radical radiotherapy for head and neck malignancies, 70%-80% of patients on chemotherapy for bone marrow transplantation, 75% of patients on high-dose chemotherapy, and 40% of patients on standard chemotherapy. The oncologic team managing this casuistics should also include a dental medicine doctor to take active part in the treatment of these patients before, during and after therapy administration because of the associated oral complications. Oral mucositis and xerostomia pose
difficulties in the intake of food and drinks, leading to malnutrition and dehydration. An array of agents with a varying therapeutic efficacy is now available for the treatment of oral mucositis. Recently, a novel agent named Gelclair, manufactured by Helsin Birex Pharmaceuticals from Dublin, Ireland, has appeared on the market. Gelclair has proved highly efficacious in the management of oral mucositis, ulcerous lesions of oral mucosa of other etiologies, postoperative wounds in oral cavity, etc. Gelclair has been approved by the US Food and Drug Administration FDA, CE and Drug Commission of the Republic of Croatia as a class 1 medical aid.


Download data is not yet available.


Zavod za javno zdravstvo FBiH. Zdravstveno statistički godišnjak Federacije Bosne i Hercegovine 2004 : 3. Sarajevo : Zavod za javno zdravstvo FBiH; 2005. p. 9-12.

Zavod za statistiku R. Hrvatske. Uzroci smrtnosti u R. Hrvatskoj. Demografski podaci. Zagreb: Zavod za statistiku R. Hrvatske; 2000.

Hrvatski zavod za javno zdravstvo. Novi slučajevi raka u R. Hrvatskoj 1999. Bilten 2000; p. 24.

Topić B. Egzogena oštećenja oralnih sluznica. In: Malić M, editor. Oralna medicina. Sarajevo : Stomatološki fakultet Univerziteta u Sarajevu; 2001. p. 67-90.

Topić B. The prevalence of precancerous lesions in primary dental health care. Radovi ANUBIH (Odjeljenje medicinskih nauka ; Centar za medicinska istraživanja). 2003;92(31; 2): 61-71.

ACS Cancer facts and figures – 1993. Atlanta: American Cancer Society; 1993.

Dautović S. Tumori. In: Malić M, editor. Oralna medicina. Sarajevo : Stomatološki fakultet Univerziteta u Sarajevu; 2001. p. 371-404.

Topić B. Oral sequels of postradiation syndrome. Radovi ANUBiH (Odjeljenje medicinskih nauka). 2004;93(33):55-62.

Cekić-Arambašin A, et al. Oralna medicina. Zagreb: Školska knjiga; 2005. p. 251.

ACS. Cancer manual. 8th ed. Boston : American Cancer Society, Massachusetts Division; 1990. Acta Medica Academica 2006;35:40-49 49

Sonis ST, Sonis AL, Lieberman A. Oral complications in patients receiving treatment for malignancies other than of the head and neck. J Am Dent Assoc. 1978;97(3):468-72.

Pico JL, Avila-Garavito A, Naccache P. Mucositis: its occurrence, consequences and treatment in the oncology setting. Oncologist. 1998;3(6):446-51.

Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer. 1993;72(5):1612-7.

Kostler WJ, Hejna M, Wenzel C, Zielinski CC. Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. CA Cancer J Clin. 2001;51(5):290-315.

Meraw SJ, Reeve CM. Dental considerations and treatment of the oncology patients receiving radiation therapy. J Am Dent Assoc. 1998;129(2):201-5.

Jansma J, Vissink A, Spijkervet FK, Roodenburg JL, Panders AK, Vermey A, et al. Protocol for the prevention and treatment of oral sequelae resulting from head and neck radiation therapy. Cancer. 1992;70(8):2171-80.

Vissink A, Burlage FR, Spijkevert FK, Jansma J, Coppes PR. Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med. 2003;14(3):213-25.

Topić B, Alajbeg I. Prevencija bakterijskog endokarditisa u praksi polivalentnog stomatologa. Stomatološki dani BiH sa internacionalnim učešćem, 2. Knjiga sažetaka. Sarajevo : Stomatološki fakultet Univerziteta u Sarajevu; 2003. p. 51.

Silverman S Jr. Oral cancer. 3rd ed. Atlanta : American Cancer Society; 1990.

Sonis ST, Fazio RC, Fang L. Principles and practice of oral medicine. 2nd ed. Philadelphia : Saunders; 1995. p. 46-54.

Fox PC. Management of dry mouth. Dent Clin North Am 1997; 41(4):863-75.

Topić B. Višestruke funkcije sline. Medix 1999; 5(25/26): 110-2.

Epstein JB, Wong FLW, Stevenson-Moore P. Osteoradionecrosis: clinical experience and a proposal

for classification. J Oral Maxillofac Surg. 1987; 45(2): 104-10.

Epstein JB, Rea G, Wong FLW, Stevenson-Moore P. Osteoradionecrosis: study of the relationship of dental extractions in patients receiving radiotherapy. Head Neck Surg. 1987; 10(1): 48-54.

Vissink A, Jansma J, Spijkervet FK, Burlage FR, Coppes RP. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med. 2003; 14(3): 199-212.

Sciubba JJ, Goldenberg D. Oral complications of radiotherapy. Lancet Oncol. 2006; 7(2): 175-83.

Myers RA, Marx RE. Use of hyperbaric oxygen in postradiation head and neck surgery. NCI Monogr. 1990; 9: 151-7.

Sheean PM. Nutrition support of blood or marrow transplant recipients: how much do we really know? Nutr Iss Gastroenterol 2005; Series 26(1): 84-97.

Šoda A. Oralni mukozitis i mogućnosti liječenja. Hrvat Stomatol Vjesn. 2006; 13(2): 10-1. 30. Brailo V. Oralne komplikacije zračenja glave i vrata. Hrvat Stomatol Vjesn. 2006; 13(2): 12-5.

Konjhodžić-Prcić A, Cekić-Arambašin A, Malić M. Incidence of radiation induced mucositis in Bosnian population. Oral Dis. 2006; 12(Suppl 1): 13-30.

Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy and radiochemotherapy. Part 2: Diagnosis and management of mucositis. Head Neck. 2004; 26(1): 77-84.

National Cancer Institute. Oral complications of chemotherapy and head/neck radiation: health professional version 2005; Available from: http://www.cancer.gov/cancertopics/pdq/supportivecare/oralcomplications/healthprofessional.

Smith F. Gelclair: managing the symptoms of oral mucositis. Hosp Med. 2001; 62(10): 623-6.

Innocenti M, Moscatelli G, Lopez S. Efficacy of gelclair in reducing pain in palliative care patients with oral lesions: preliminary findings from an open pilot study. J Pain Symptom Manage. 2002; 24(5): 456-7.

Bonassi L, Cotroneo G, Nastasi G. Treatment with Gelclair in patients suffering grade III-IV oral mucositis: efficacy and impact on quality of life (QOL). Ann Oncol. 2003; 14(Suppl 4, Abstract 38): 58.

Berndtson M. Preliminary study of Orassist (Gelclair) in the management of oral mucositis. Swed Hosp Dent. 2001; 26(1): 17-21.

Hita-Iglesias D, Torres-Legares D, Gutierrez- Perez JL. Evaluation of the clinical behaviour of a polyvinylpyrrolidone and sodium hyalonurate gel (Gelclair) in patients subjected to surgical treatment with CO2 laser. Int J Oral Maxillofac Surg.

; 35(6): 514-7.

Topić B, Cekić-Arambašin A, Malčić S. Oral lichen ruber (OLR) epidemiology and clinical findings in 143 cases. Acta Stomatol Croat. 1996; 30(2): 111-5.




How to Cite

Topić, B., & Cekić-Arambašin, A. (2006). Oral Mucositis. Acta Medica Academica, 35(1), 40–49. Retrieved from https://www.ama.ba/index.php/ama/article/view/12



Review Articles

Most read articles by the same author(s)